Capitalizing on its rising stock price driven by avian flu fears, Novavax Inc. is bringing in $18 million through a public offering to support clinical development. (BioWorld Today)
Shares of Nabi Biopharmaceuticals plunged 71.8 percent after the company halted further development of StaphVAX pending a deeper data analysis, as the product missed its primary endpoint in a Phase III trial to treat Staphylococcus aureus-caused infections in patients with end-stage renal disease. (BioWorld Today)
Shares of Nabi Biopharmaceuticals plunged 71.8 percent after the company halted further development of StaphVAX pending a deeper data analysis, as the product missed its primary endpoint in a Phase III trial to treat Staphylococcus aureus-caused infections in patients with end-stage renal disease. (BioWorld Today)
